文献速递临床试验与 GCP流行病学与生物统计

雾化镁联合沙丁胺醇对难治性儿童急性哮喘住院率的影响:随机临床试验

Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该随机双盲平行组试验在加拿大7个三级儿童急诊科纳入818例2至17岁难治性急性哮喘患儿,比较雾化硫酸镁与5.5%盐水安慰剂联合沙丁胺醇的疗效。

要点

  • 雾化镁联合沙丁胺醇未显著降低24小时内哮喘住院率
  • PRAM评分、呼吸频率、氧饱和度和血压等次要结局均无显著差异
  • 镁组恶心呕吐或咽喉鼻部不适发生率为4%,安慰剂组为1%

核心结论

  • 在急诊难治性急性哮喘患儿中,雾化镁联合沙丁胺醇较安慰剂联合沙丁胺醇未显著降低24小时内哮喘住院率。
  • 研究结果不支持在难治性急性哮喘患儿中使用雾化镁联合沙丁胺醇。

研究设计与样本

  • 随机双盲平行组临床试验,2011年9月26日至2019年11月19日在加拿大7个三级儿童急诊科开展。
  • 818例2至17岁、经口服糖皮质激素及3次吸入沙丁胺醇和异丙托溴铵治疗1小时后PRAM评分≥5分(12分制)的患儿被随机分组,816例完成试验。
  • 镁组410例、安慰剂组408例,均接受3次雾化沙丁胺醇治疗。

主要发现

  • PRAM评分变化组间差异为0.14分(95%CI -0.23至0.50,P=0.46),无统计学意义。
  • 镁组17/409例(4%)出现恶心呕吐或咽喉鼻部不适,安慰剂组5/407例(1%)。

临床怎么用

  • 对于急诊中经初始治疗后仍处于中重度呼吸窘迫的儿童急性哮喘,不应常规加用雾化镁以预防住院。
  • 临床决策可继续依据指南推荐的初始治疗与密切评估,而非依赖雾化镁降低住院风险。

局限性

  • 研究仅纳入加拿大7个三级儿童急诊科的就诊患儿,外推至其他医疗环境需谨慎。
  • 住院率组间差异的95%CI上限为2.8%,不能完全排除小幅获益或危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While intravenous magnesium decreases hospitalizations in refractory pediatric acute asthma, it is variably used because of invasiveness and safety concerns. The benefit of nebulized magnesium to prevent hospitalization is unknown. OBJECTIVE: To evaluate the effectiveness of nebulized magnesium in children with acute asthma remaining in moderate or severe respiratory distress after initial therapy. DESIGN, SETTING, AND PARTICIPANTS: A randomized double-blind parallel-group clinical trial from September 26, 2011, to November 19, 2019, in 7 tertiary-care pediatric emergency departments in Canada. The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments. Of 5846 screened patients, 4332 were excluded for criteria, 273 declined participation, 423 otherwise excluded, 818 randomized, and 816 analyzed. INTERVENTIONS: Participants were randomized to 3 nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n = 408). MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for asthma within 24 hours. Secondary outcomes included PRAM score; respiratory rate; oxygen saturation at 60, 120, 180, and 240 minutes; blood pressure at 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes. RESULTS: Among 818 randomized patients (median age, 5 years; 63% males), 816 completed the trial (409 received magnesium; 407, placebo). A total of 178 of the 409 children who received magnesium (43.5%) were hospitalized vs 194 of the 407 who received placebo (47.7%) (difference, -4.2%; absolute risk difference 95% [exact] CI, -11% to 2.8%]; P = .26). There were no significant between-group differences in changes from baseline to 240 minutes in PRAM score (difference of changes, 0.14 points [95% CI, -0.23 to 0.50]; P = .46); respiratory rate (0.17 breaths/min [95% CI, -1.32 to 1.67]; P = .82); oxygen saturation (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.03]; P = .50); or mean number of additional albuterol treatments (magnesium: 1.49, placebo: 1.59; risk ratio, 0.94 [95% CI, 0.79 to 1.11]; P = .47). Nausea/vomiting or sore throat/nose occurred in 17 of the 409 children who received magnesium (4%) and 5 of the 407 who received placebo (1%). CONCLUSIONS AND RELEVANCE: Among children with refractory acute asthma in the emergency department, nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours. The findings do not support use of nebulized magnesium with albuterol among children with refractory acute asthma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01429415.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Schuh S, Sweeney J, Rumantir M, et al. Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. JAMA. 2020. PMID: 33231663. doi:10.1001/jama.2020.19839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。